AA
NKTR icon

Apriem Advisors’s Nektar Therapeutics NKTR Stock Holding History

Apriem Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-7
Closed -$1K – 557
2015
Q3 		$1K Hold
7
– – ﹤0.01% 498
2015
Q2 		$1K Hold
7
– – ﹤0.01% 603
2015
Q1 		$1K Hold
7
– – ﹤0.01% 538
2014
Q4 		$2K Hold
7
– – ﹤0.01% 484
2014
Q3 		$1K Hold
7
– – ﹤0.01% 503
2014
Q2 		$1K Buy
+7
New +$1.24K ﹤0.01% 461

Other funds holding NKTR

O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Apriem Advisors's NKTR Position: Q4 2015 in Review

Apriem Advisors sold out of Nektar Therapeutics (NKTR) in Q4 2015, closing a stake of 7 shares — an estimated $1K sold.

Apriem Advisors first reported a position in NKTR in Q2 2014 and held it in 6 quarters. The position peaked at $2K in Q4 2014. 179 funds tracked by Wall St. Rank hold NKTR as of Q4 2015.

  • Apriem Advisors reported no remaining Nektar Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Apriem Advisors sold 7 Nektar Therapeutics shares in Q4 2015, an estimated $1K.
  • Apriem Advisors first reported a position in Nektar Therapeutics in Q2 2014 and held it in 6 quarters.
  • Apriem Advisors's Nektar Therapeutics position peaked at $2K in Q4 2014.
  • 179 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2015.

Based on Apriem Advisors's 13F filing for Q4 2015, filed 9 Feb 2016.